A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects with Metastatic Urothelial Cancer
This is an open-label, multicenter, dose escalation study examining the safety and PK of AGS15E administered as monotherapy in subjects with metastatic urothelial cancer.
Study Number: 

PH 246213

Early Phase
Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.